Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECISE-PCI: Genotype-Guided vs Conventional DAPT in ACS
NCT06283888Phase 4Recruiting
- Sponsor
- Zunyi Medical University
- Start
- Apr 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ticagrelor and clopidogrel in acute coronary syndrome (ACS) (2 arms), sponsored by Zunyi Medical University. Primary endpoint: Net Adverse Clinical Events at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
ticagrelorclopidogrel
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06283888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283888.